S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.22%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.22%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.22%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.22%)
Log in
OTCMKTS:NSPX

Inspyr Therapeutics Competitors

$0.01
0.00 (0.00 %)
(As of 03/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.02
50-Day Range
$0.01
MA: $0.02
$0.04
52-Week Range
$0.00
Now: $0.01
$1.13
Volume15.25 million shs
Average Volume27.30 million shs
Market Capitalization$1.83 million
P/E RatioN/A
Dividend YieldN/A
Beta-16.55

Competitors

Inspyr Therapeutics (OTCMKTS:NSPX) Vs. WCUI, IPCIF, ISCO, KAYS, ABMC, and COTQF

Should you be buying NSPX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Inspyr Therapeutics, including Wellness Center USA (WCUI), Intellipharmaceutics International (IPCIF), International Stem Cell (ISCO), Kaya (KAYS), American Bio Medica (ABMC), and Cotinga Pharmaceuticals (COTQF).

Inspyr Therapeutics (OTCMKTS:NSPX) and Wellness Center USA (OTCMKTS:WCUI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Profitability

This table compares Inspyr Therapeutics and Wellness Center USA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inspyr TherapeuticsN/AN/A-298.11%
Wellness Center USAN/AN/A-1,809.19%

Earnings & Valuation

This table compares Inspyr Therapeutics and Wellness Center USA's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspyr TherapeuticsN/AN/A$-930,000.00N/AN/A
Wellness Center USA$30,000.00209.96$-2,390,000.00N/AN/A

Inspyr Therapeutics has higher earnings, but lower revenue than Wellness Center USA.

Volatility and Risk

Inspyr Therapeutics has a beta of -16.55, meaning that its stock price is 1,755% less volatile than the S&P 500. Comparatively, Wellness Center USA has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Inspyr Therapeutics and Wellness Center USA, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inspyr Therapeutics0000N/A
Wellness Center USA0000N/A

Institutional & Insider Ownership

0.1% of Wellness Center USA shares are held by institutional investors. 0.0% of Inspyr Therapeutics shares are held by company insiders. Comparatively, 14.1% of Wellness Center USA shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Wellness Center USA beats Inspyr Therapeutics on 4 of the 6 factors compared between the two stocks.

Intellipharmaceutics International (OTCMKTS:IPCIF) and Inspyr Therapeutics (OTCMKTS:NSPX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Intellipharmaceutics International and Inspyr Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intellipharmaceutics International-232.11%N/A-81.71%
Inspyr TherapeuticsN/AN/A-298.11%

Risk & Volatility

Intellipharmaceutics International has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Inspyr Therapeutics has a beta of -16.55, indicating that its stock price is 1,755% less volatile than the S&P 500.

Earnings & Valuation

This table compares Intellipharmaceutics International and Inspyr Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellipharmaceutics International$3.48 million1.96$-8,090,000.00N/AN/A
Inspyr TherapeuticsN/AN/A$-930,000.00N/AN/A

Inspyr Therapeutics has lower revenue, but higher earnings than Intellipharmaceutics International.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Intellipharmaceutics International and Inspyr Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intellipharmaceutics International0000N/A
Inspyr Therapeutics0000N/A

Summary

Intellipharmaceutics International beats Inspyr Therapeutics on 3 of the 5 factors compared between the two stocks.

Inspyr Therapeutics (OTCMKTS:NSPX) and International Stem Cell (OTCMKTS:ISCO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Earnings and Valuation

This table compares Inspyr Therapeutics and International Stem Cell's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspyr TherapeuticsN/AN/A$-930,000.00N/AN/A
International Stem Cell$9.47 million0.70$-4,260,000.00N/AN/A

Inspyr Therapeutics has higher earnings, but lower revenue than International Stem Cell.

Analyst Ratings

This is a summary of current recommendations for Inspyr Therapeutics and International Stem Cell, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inspyr Therapeutics0000N/A
International Stem Cell0000N/A

Profitability

This table compares Inspyr Therapeutics and International Stem Cell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inspyr TherapeuticsN/AN/A-298.11%
International Stem Cell-55.56%N/A-72.21%

Risk and Volatility

Inspyr Therapeutics has a beta of -16.55, indicating that its share price is 1,755% less volatile than the S&P 500. Comparatively, International Stem Cell has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.

Summary

International Stem Cell beats Inspyr Therapeutics on 3 of the 5 factors compared between the two stocks.

Inspyr Therapeutics (OTCMKTS:NSPX) and Kaya (OTCMKTS:KAYS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Inspyr Therapeutics and Kaya's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspyr TherapeuticsN/AN/A$-930,000.00N/AN/A
Kaya$1.01 million5.65$7.80 millionN/AN/A

Kaya has higher revenue and earnings than Inspyr Therapeutics.

Volatility and Risk

Inspyr Therapeutics has a beta of -16.55, indicating that its share price is 1,755% less volatile than the S&P 500. Comparatively, Kaya has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.

Profitability

This table compares Inspyr Therapeutics and Kaya's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inspyr TherapeuticsN/AN/A-298.11%
Kaya-1,558.07%N/A-586.93%

Analyst Recommendations

This is a breakdown of current ratings for Inspyr Therapeutics and Kaya, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inspyr Therapeutics0000N/A
Kaya01002.00

Summary

Kaya beats Inspyr Therapeutics on 3 of the 5 factors compared between the two stocks.

American Bio Medica (OTCMKTS:ABMC) and Inspyr Therapeutics (OTCMKTS:NSPX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares American Bio Medica and Inspyr Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
American Bio Medica-18.99%N/A-35.34%
Inspyr TherapeuticsN/AN/A-298.11%

Risk & Volatility

American Bio Medica has a beta of -1.45, indicating that its share price is 245% less volatile than the S&P 500. Comparatively, Inspyr Therapeutics has a beta of -16.55, indicating that its share price is 1,755% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for American Bio Medica and Inspyr Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
American Bio Medica0000N/A
Inspyr Therapeutics0000N/A

Earnings and Valuation

This table compares American Bio Medica and Inspyr Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Bio Medica$3.65 million1.55$-680,000.00N/AN/A
Inspyr TherapeuticsN/AN/A$-930,000.00N/AN/A

American Bio Medica has higher revenue and earnings than Inspyr Therapeutics.

Summary

American Bio Medica beats Inspyr Therapeutics on 4 of the 5 factors compared between the two stocks.

Cotinga Pharmaceuticals (OTCMKTS:COTQF) and Inspyr Therapeutics (OTCMKTS:NSPX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Risk and Volatility

Cotinga Pharmaceuticals has a beta of 43.44, indicating that its stock price is 4,244% more volatile than the S&P 500. Comparatively, Inspyr Therapeutics has a beta of -16.55, indicating that its stock price is 1,755% less volatile than the S&P 500.

Profitability

This table compares Cotinga Pharmaceuticals and Inspyr Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cotinga PharmaceuticalsN/AN/AN/A
Inspyr TherapeuticsN/AN/A-298.11%

Earnings & Valuation

This table compares Cotinga Pharmaceuticals and Inspyr Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cotinga PharmaceuticalsN/AN/A$-2,050,000.00N/AN/A
Inspyr TherapeuticsN/AN/A$-930,000.00N/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Cotinga Pharmaceuticals and Inspyr Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cotinga Pharmaceuticals0000N/A
Inspyr Therapeutics0000N/A

Summary

Cotinga Pharmaceuticals beats Inspyr Therapeutics on 2 of the 3 factors compared between the two stocks.


Inspyr Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
WCUI
Wellness Center USA
0.5$0.06flat$7.25 million$30,000.000.00
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.29flat$6.82 million$3.48 million-2.40Decrease in Short Interest
Gap Up
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.88flat$6.63 million$9.47 million0.00Gap Up
KAYS
Kaya
0.7$0.40flat$5.71 million$1.01 million0.00Increase in Short Interest
Gap Up
ABMC
American Bio Medica
0.5$0.14flat$5.65 million$3.65 million0.00Upcoming Earnings
Increase in Short Interest
Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.23flat$5.28 millionN/A-2.56Gap Up
AMBS
Amarantus BioScience
0.0$0.01flat$4.79 millionN/A0.00Gap Up
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01Increase in Short Interest
Innovus Pharmaceuticals logo
INNV
Innovus Pharmaceuticals
0.5$24.20flat$3.94 million$23.99 million-7.40High Trading Volume
News Coverage
AKRXQ
Akorn
0.1$0.03flat$3.60 million$682.43 million-0.01
WHCA
Williston
0.0$0.25flat$3.40 millionN/A0.00
IMUCD
ImmunoCellular Therapeutics
0.0$0.80flat$3.35 millionN/A0.00High Trading Volume
RSPI
RespireRx Pharmaceuticals
0.5$0.04flat$3.06 millionN/A-0.08
BTHE
Boston Therapeutics
0.5$0.03flat$2.95 million$20,000.00-1.44Gap Up
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
IMUC
ImmunoCellular Therapeutics
0.0$0.81flat$2.82 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
IMNPQ
Immune Pharmaceuticals
0.0$0.01flat$2.28 millionN/A0.00Gap Up
ETST
Earth Science Tech
0.5$0.04flat$2.19 million$530,000.000.00Gap Down
VVUSQ
VIVUS
0.6$0.12flat$2.10 million$69.76 million-0.04
FWDG
FutureWorld
0.5$0.00flat$1.97 millionN/A0.00Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.10flat$1.87 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01flat$1.86 millionN/A0.00Decrease in Short Interest
CAPS
Capstone Therapeutics
0.8$34.00flat$1.84 million$2 million0.00
AKAOQ
Achaogen
0.6$0.02flat$1.73 million$8.73 million0.00Gap Up
CDXI
Cardax
0.0$2.00flat$1.59 million$710,000.000.00
AOXG
Aoxing Pharmaceutical
0.5$0.02flat$1.52 millionN/A0.00Gap Up
MLNTQ
Melinta Therapeutics
0.2$0.11flat$1.51 million$96.43 million0.00
SPHS
Sophiris Bio
0.1$0.03flat$1.24 millionN/A0.00Gap Down
VGLS
VG Life Sciences
0.0$0.01flat$1.22 millionN/A0.00Gap Down
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.05flat$1.21 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
ATRX
Adhera Therapeutics
0.0$0.12flat$1.17 million$250,000.000.00Upcoming Earnings
Gap Up
PPCB
Propanc Biopharma
0.7$0.23flat$1.01 millionN/A0.00News Coverage
SNNAQ
Sienna Biopharmaceuticals
0.5$0.04flat$927,000.00N/A0.00Gap Up
WWHC
W World
0.8$3.00flat$885,000.00N/A0.00Decrease in Short Interest
News Coverage
HSTC
HST Global
0.8$0.15flat$782,000.00N/A0.00High Trading Volume
Gap Up
STLT
Spotlight Innovation
0.5$0.01flat$772,000.00N/A0.00
BSPM
Biostar Pharmaceuticals
0.0$0.25flat$660,000.00N/A0.00Gap Up
PXYN
Praxsyn
0.6$0.00flat$594,000.00N/A0.00Decrease in Short Interest
News Coverage
Gap Down
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05flat$572,000.00$1.90 million0.00News Coverage
SKVI
Skinvisible
0.7$0.12flat$537,000.00$40,000.000.00Upcoming Earnings
High Trading Volume
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01flat$410,000.00N/A0.00Gap Up
TRPXD
Therapix Biosciences
0.0$7.75flat$388,000.00N/A0.00High Trading Volume
Gap Up
PZRXQ
PhaseRx
0.2$0.03flat$362,000.00N/A0.00Gap Down
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47flat$338,000.00$36.55 million0.00Gap Up
WDBG
Woodbrook Group
0.0$2.00flat$280,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.12flat$220,000.00N/A0.00Gap Down
AXMP
AXM Pharma
0.2$0.00flat$203,000.00N/A0.00
OREXQ
Orexigen Therapeutics
0.4$0.01flat$100,000.00$33.71 million0.00Gap Up
MTST
MetaStat
0.0$0.01flat$77,000.00$20,000.000.00
ALSE
Alseres Pharmaceuticals
0.0$6.00flat$36,000.00N/A0.00
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.